IP ALT-803 Followed by SQ ALT-803 for Ovarian Cancer

Inclusion Criteria * Diagnosis of FIGO stage III or grade IV epithelial ovarian, fallopian tube or primary peritoneal carcinoma, has received at least 3 cycles of first line IV/IP cisplatin and paclitaxel chemotherapy and has stable disease or better - refer to Appendix II for FIGO staging system (Note: to be eligible for this study, the patient must receive a minimum of 3 cycles of IP therapy; however, patients may continue on IV only 1st line therapy for additional cycles as long as inclusion criteria 4.1.2 is met) * Able to begin study therapy within 3 months of final dose of first line chemotherapy * Functioning intraperitoneal catheter * ≥ 18 years of age * GOG performance status ≤ 2 (Appendix II) * Adequate organ function within 14 days of enrollment defined as: * Hematology: hemoglobin ≥ 8 g/dl, absolute neutrophil count (ANC) ≥ 1500/ul, platelets ≥ 50 x 109/L * Creatinine: ≤ 2.0 mg/dL * Hepatic: SGOT and SGPT ≤ 3 x upper limit of institutional normal (ULN) * Ability to be off prednisone and other immunosuppressive drugs for at least 3 days prior to and while receiving ALT-803 * Voluntary written consent prior to the performance of any research related procedures Exclusion Criteria * Received any investigational agent within the 14 days before the start of ALT-803 * Class II or greater New York Heart Association Functional Classification criteria (Appendix II) or serious cardiac arrhythmias likely to increase the risk of cardiac complications of cytokine ther…